Glucagon-like peptide-1: difference between revisions
Diff·revision 28 → 29·01:54, 9 Nov 2024
Difference between revision 28 and revision 29 of Glucagon-like peptide-1. 4 lines changed; the page grew by 202 bytes.
| Revision 28 — 06:55, 2 Nov 2024 HalfLifeHavel (talk) expand §Therapeutic exploitation 7,886 bytes +44 | Revision 29 — 01:54, 9 Nov 2024 IncretinIvo (talk) replace bare ref with full citation 8,088 bytes +202 | ||
|---|---|---|---|
| 12 | | Monoisotopic mass = ≈3,297 Da (7–36 amide) | 12 | | Monoisotopic mass = ≈3,297 Da (7–36 amide) |
| 13 | | Sequence position = Proglucagon 78–107 | 13 | | Sequence position = Proglucagon 78–107 |
| + | 14 | <!-- Pharmacokinetics --> | |
| + | 15 | | Plasma half-life = 1.5–2 minutes | |
| + | 16 | | Primary inactivation = [[Dipeptidyl peptidase-4|DPP-4]] cleavage at Ala<sup>8</sup> | |
| + | 17 | | Secondary clearance = Renal; neutral endopeptidase | |
| 14 | }} | 18 | }} |
| 15 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} | 19 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} |